Endocrine Abstracts

Background: Cardiovascular events are the major cause of mortality among patients with type 2 diabetes mellitus (DM2). Menopause in women additionally increases cardiovascular risk. Despite myocardial infarction (MI) treatment approach in diabetic patients is not specific, some glucose-lowering drugs could have cardioprotective properties. In general, most glucagon-like peptide-1 receptor agonists (GLP-1Ra) and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have cardiova...

Background:Myocardial infarction (MI) is one of the leading causes of mortality in patients with type 2 diabetes mellitus (DM), therefore it is essential to give preference to a glucose-lowering drug having most prominent cardioprotective properties. Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) have demonstrated an ability to decrease heart failure manifestations, cardiovascular death frequency not having a certain influence on MI occurrence. On ...